ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
49 hedge funds and large institutions have $259M invested in Adaptimmune Therapeutics in 2016 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
Holders
49
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$80.3M | |
| 2 | +$4.65M | |
| 3 | +$3.95M | |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$3.49M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.44M |
Top Sellers
| 1 | -$3.92M | |
| 2 | -$2.55M | |
| 3 | -$1.7M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.57M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.3M |